Danaher (NYSE:DHR – Get Free Report) and Oncology Institute (NASDAQ:TOI – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
Valuation & Earnings
This table compares Danaher and Oncology Institute”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Danaher | $24.57 billion | 5.23 | $3.61 billion | $5.17 | 35.12 |
| Oncology Institute | $502.73 million | 1.00 | -$60.61 million | ($0.37) | -13.78 |
Insider and Institutional Ownership
79.1% of Danaher shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 10.8% of Danaher shares are owned by company insiders. Comparatively, 4.4% of Oncology Institute shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current recommendations for Danaher and Oncology Institute, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Danaher | 0 | 5 | 19 | 1 | 2.84 |
| Oncology Institute | 1 | 0 | 4 | 0 | 2.60 |
Danaher currently has a consensus target price of $233.61, suggesting a potential upside of 28.66%. Oncology Institute has a consensus target price of $7.25, suggesting a potential upside of 42.16%. Given Oncology Institute’s higher probable upside, analysts clearly believe Oncology Institute is more favorable than Danaher.
Profitability
This table compares Danaher and Oncology Institute’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Danaher | 14.89% | 10.91% | 6.94% |
| Oncology Institute | -7.42% | N/A | -24.68% |
Volatility and Risk
Danaher has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.
Summary
Danaher beats Oncology Institute on 14 of the 15 factors compared between the two stocks.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
About Oncology Institute
-logo-1200x675.png?v=20220303080937){kind=logo}
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
